These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 10507277)

  • 1. Compliance and the rehabilitation alliance.
    Aquila R; Weiden PJ; Emanuel M
    J Clin Psychiatry; 1999; 60 Suppl 19():23-7; discussion 28-9. PubMed ID: 10507277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
    Chue P
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long term--maximising potential for rehabilitation in patients with schizophrenia.
    Fagiolini A; Goracci A
    Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S123-9. PubMed ID: 17336767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial response to antipsychotic treatment: the patient with enduring symptoms.
    Emsley RA
    J Clin Psychiatry; 1999; 60 Suppl 23():10-3. PubMed ID: 10625194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
    Kasper S
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choosing an atypical antipsychotic.
    Sussman N
    Int Clin Psychopharmacol; 2002 Aug; 17 Suppl 3():S29-33. PubMed ID: 12570069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving patient outcomes in schizophrenia: achieving remission.
    Nasrallah HA; Lasser R
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):57-61. PubMed ID: 17046987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients.
    Høiberg MP; Nielsen B
    Nord J Psychiatry; 2006; 60(3):207-12. PubMed ID: 16720511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
    Misdrahi D; Llorca PM; Lançon C; Bayle FJ
    Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment.
    Gerlach J
    J Clin Psychiatry; 1999; 60 Suppl 23():20-4. PubMed ID: 10625196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia.
    Nasrallah HA; Tandon R
    J Clin Psychiatry; 2002; 63 Suppl 13():12-20. PubMed ID: 12562142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
    Bhanji NH; Chouinard G; Margolese HC
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term phase of schizophrenia: impact of atypical agents.
    Naber D
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S11-4. PubMed ID: 11252518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neuroleptics--psychotherapy--psychiatric social work. In schizophrenia help is needed from many sides].
    Klingberg S; Längle G; Buchkremer G
    MMW Fortschr Med; 2003 Oct; 145(41):28-31. PubMed ID: 14655477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient treatment: community and private practice support systems.
    Gallant DM
    J Clin Psychiatry; 1983 Jun; 44(6 Pt 2):15-22. PubMed ID: 6133852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs.
    Gaebel W
    Int Clin Psychopharmacol; 1997 Feb; 12 Suppl 1():S37-42. PubMed ID: 9179642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-extrapyramidal motor side-effects in long-term therapy with neuroleptics: an analysis of 99 patients].
    Ginzel I; Hilger E; Barnas C
    Wien Klin Wochenschr; 2002 Jan; 114(1-2):38-43. PubMed ID: 12407934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.